CDR-Life Hits Milestone in 'Immune Reset' Therapy with Boehringer

ZURICH, SWITZERLAND – March 23, 2026 – In a significant step forward for autoimmune disease treatment, Swiss biotechnology firm CDR-Life announced it has achieved a critical preclinical milestone in its partnership with pharmaceutical giant Boehringer Ingelheim. The achievement triggers an undisclosed payment and advances the development of a novel therapy, CDR111, designed to deliver a therapeutic “reset” to the immune systems of patients suffering from debilitating conditions like lupus and multiple sclerosis.

The collaboration, first established in November 2025 with a potential value of up to $570 million, combines CDR-Life's precision antibody engineering with Boehringer Ingelheim's global development and commercialization power. This latest milestone, based on successful in vitro and in vivo proof-of-concept studies, has prompted Boehringer Ingelheim to move the candidate forward, signaling strong confidence in its potential to transform the treatment landscape.

A Precision Strike Against Autoimmune Disease

At the heart of the collaboration is CDR-Life’s proprietary M-gager® platform and the candidate it produced, CDR111. This isn't just another immunosuppressant; it's a highly specialized weapon known as a trispecific T cell engager. Its mission is to selectively hunt down and eliminate dysregulated B cells, the immune cells that go rogue and mistakenly attack the body's own tissues in many autoimmune diseases.

Unlike broad-spectrum treatments that suppress the entire immune system and leave patients vulnerable to infection, CDR111 is engineered for precision. It works by forming a bridge: one part of the molecule grabs onto the target B cell, while another part engages a patient’s own T cells—the immune system's natural killers. This connection activates the T cells to destroy the targeted B cells with high specificity.

The goal is profound B-cell depletion, creating an opportunity for the immune system to rebuild itself in a more balanced, non-self-attacking state. This concept, often called an “immune system reset,” is gaining significant traction as a potential pathway to long-term, drug-free remission. It represents a paradigm shift away from the chronic management of symptoms toward a potentially disease-modifying intervention.

“This milestone reflects the strength of our antibody-derived platform and its ability to rapidly generate highly potent, selective molecules,” said Christian Leisner, PhD, Chief Executive Officer of CDR-Life, in a statement. “We are excited to see continued momentum in our partnership with Boehringer Ingelheim and look forward to further advancements of this program.”

The Power of a Strategic Partnership

The alliance between the nimble Zurich-based biotech and the German pharmaceutical titan exemplifies a key trend in drug development. For CDR-Life, the partnership provides crucial validation for its M-gager® technology and non-dilutive funding to advance its broader pipeline. The 2025 licensing agreement included approximately $48 million in upfront and near-term payments, with the potential for a total of $570 million plus future royalties.

For Boehringer Ingelheim, the deal secures a promising, potentially first-in-class asset that strengthens its immunology portfolio. The company has been actively investing in next-generation autoimmune therapies, forging similar alliances with companies like Cue Biopharma for other B-cell depletion strategies. This move underscores a clear corporate strategy to move beyond symptomatic relief and invest in therapies that target the root cause of disease.

This is not the first time the two companies have joined forces. A long-standing prior collaboration resulted in BI 771716, an investigational antibody fragment for the eye disease geographic atrophy, which was developed by Boehringer Ingelheim using CDR-Life's technology and is currently in Phase 2 trials. The success of that initial partnership undoubtedly paved the way for this more expansive agreement in the high-stakes autoimmune field.

Addressing a Vast Unmet Need

The potential market for a therapy like CDR111 is immense, driven by the millions of patients grappling with the physical, emotional, and financial toll of autoimmune diseases. The global market for autoimmune therapeutics is projected to exceed $185 billion by 2030, yet significant unmet needs persist across major indications.

In systemic lupus erythematosus (SLE), for instance, patients often rely on high-dose corticosteroids with severe side effects, and many struggle to achieve lasting remission. For progressive forms of multiple sclerosis (MS), there are few effective treatments that can halt or reverse disability. Even in rheumatoid arthritis, where biologic drugs have improved outcomes, a substantial portion of patients fail to respond adequately to existing treatments.

A therapy capable of inducing a deep and durable immune reset could offer a transformative benefit, reducing reliance on chronic medications and their associated toxicities. The prospect of a treatment that could potentially lead to long periods of remission without continuous therapy represents the holy grail for both patients and clinicians in this therapeutic area.

Validating a Versatile Platform

While the autoimmune program captures headlines, this milestone also casts a bright light on the versatility of CDR-Life's underlying M-gager® technology. The company is concurrently advancing a robust pipeline of T cell engagers for hard-to-treat solid tumors, demonstrating the platform's adaptability across different disease types with distinct biological challenges.

Its lead oncology candidate, CDR404, is a T cell engager targeting MAGE-A4-positive cancers and is already in Phase 1 clinical trials. Other programs are aimed at well-known cancer antigens like PRAME and KK-LC-1. The ability to successfully develop potent molecules for both intracellular cancer targets and cell-surface autoimmune targets showcases the platform's sophistication and breadth.

Backed by a $76 million Series A financing round from a syndicate of leading cross-Atlantic investors, CDR-Life has built a solid foundation for growth. As Boehringer Ingelheim now shepherds CDR111 through the next stages of development, CDR-Life can continue to leverage its validated platform to build a new generation of targeted immunotherapies for diseases with the highest unmet need.